Alexander Greenshields-Watson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alexander Greenshields-Watson has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Charlotte Mary Deane
Oxford Protein Informatics Group, Department of Statistics, University of Oxford, Oxford OX1 3LB, UK
9 shared publications - Pierre J. Rizkallah
Cardiff University
5 shared publications Parth Agarwal
Oxford Protein Informatics Group, Department of Statistics, University of Oxford, 24-29 St Giles’, Oxford, OX1 3LB United Kingdom
4 shared publications- David K. Cole
Division of Infection and Immunity and Systems Immunity Research Institute, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom
3 shared publications - Fabian C. Spoendlin
Department of Statistics, University of Oxford, Oxford, UK
3 shared publications - Fergus Boyles
Department of Statistics, University of Oxford
3 shared publications
Latest Publications
- Open Access
Fast retrieval of structurally similar antibodies from large sequence databases with AbSLang
The first steps in antibody therapeutic discovery involve identification of sequences with desirable binding properties. A way of finding these lead molecules is through the search of large sequence databases. Current methods, due to the size of databases, rely on germline or complementarity-determining-region (CDR) sequence identities, overlooking structurally similar antibodies with divergent sequences which can have identical binding properties . To address this, we introduce AbSLang, a model trained for pairwise CDR RMSD prediction using a contrastive learning approach. We demonstrate that AbSLang has comparable accuracy to exact RMSD calculation after explicit structure prediction with state-of-the-art models. Building on this model, we implemented AbSLang-search, a pipeline for retrieval of structurally similar antibodies from large sequence databases. AbSLang-search is highly compute efficient and allows to search datasets with 10 million sequences in less than 2 seconds.
Open AccessFast retrieval of structurally similar antibodies from large sequence databases with AbSLang
The first steps in antibody therapeutic discovery involve identification of sequences with desirable binding properties. A way of finding these lead molecules is through the search of large sequence databases. Current methods, due to the size of databases, rely on germline or complementarity-determining-region (CDR) sequence identities, overlooking structurally similar antibodies with divergent sequences which can have identical binding properties . To address this, we introduce AbSLang, a model trained for pairwise CDR RMSD prediction using a contrastive learning approach. We demonstrate that AbSLang has comparable accuracy to exact RMSD calculation after explicit structure prediction with state-of-the-art models. Building on this model, we implemented AbSLang-search, a pipeline for retrieval of structurally similar antibodies from large sequence databases. AbSLang-search is highly compute efficient and allows to search datasets with 10 million sequences in less than 2 seconds.
- Open Access
- 21 February 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
LICHEN enables light-chain immunoglobulin sequence generation conditioned on the heavy chain and experimental needs
In developing therapeutic antibodies, the heavy chain is often prioritised due to its higher variability and its central role in antigen binding. An appropriate pairing of the light sequence is however important for antibody function. Here we present LICHEN, a heavy chain conditioned light sequence generation tool that enables collaborative light sequence design by leveraging computational capabilities alongside experimental expertise. LICHEN generates light sequences which are valid (antibody-like), diverse in sequence and structure, and conditioned on a specific heavy chain. LICHEN can also condition on germline and CDRs and automatically filter generated sequences for required properties. We carry out experimental validation of the method conditioning only on the heavy sequence and on the heavy sequence and binding information. Our in vitro results show that sequences created by LICHEN have effective expression yields and can retain antigen-binding. LICHEN can thus be used across multiple antibody engineering scenarios for efficient light-chain pairing.
- 21 February 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessLICHEN enables light-chain immunoglobulin sequence generation conditioned on the heavy chain and experimental needs
In developing therapeutic antibodies, the heavy chain is often prioritised due to its higher variability and its central role in antigen binding. An appropriate pairing of the light sequence is however important for antibody function. Here we present LICHEN, a heavy chain conditioned light sequence generation tool that enables collaborative light sequence design by leveraging computational capabilities alongside experimental expertise. LICHEN generates light sequences which are valid (antibody-like), diverse in sequence and structure, and conditioned on a specific heavy chain. LICHEN can also condition on germline and CDRs and automatically filter generated sequences for required properties. We carry out experimental validation of the method conditioning only on the heavy sequence and on the heavy sequence and binding information. Our in vitro results show that sequences created by LICHEN have effective expression yields and can retain antigen-binding. LICHEN can thus be used across multiple antibody engineering scenarios for efficient light-chain pairing.
- Open Access
- 24 October 2025
- Published by Elsevier in Journal of Molecular Biology
- Vol. 438 (18) , 169509
HeavyBuilder: Analysis of High-Throughput of Antibody Heavy Chain Repertoires in the Structural Space
- 24 October 2025
- Published by Elsevier in Journal of Molecular Biology
- Vol. 438 (18) , 169509
Open AccessHeavyBuilder: Analysis of High-Throughput of Antibody Heavy Chain Repertoires in the Structural Space
- Open Access
LICHEN: Light-chain Immunoglobulin sequence generation Conditioned on the Heavy chain and Experimental Needs
In developing therapeutic antibodies, the heavy chain is often prioritised due to its higher variability and its central role in antigen binding. An appropriate pairing of the light sequence is however important for antibody function. Here we present LICHEN, a heavy chain conditioned light sequence generation tool that enables collaborative light sequence design by leveraging computational capabilities alongside experimental expertise. LICHEN generates light sequences which are valid (antibodylike), diverse in sequence and structure, and conditioned on a specific heavy chain. LICHEN can also condition on germline and CDRs and automatically filter generated sequences for required properties. This allows LICHEN to be used across multiple antibody development use cases. We carry out experimental validation of the method conditioning only on the heavy sequence and on the heavy sequence and binding information. Our in vitro results show that sequences created by LICHEN have effective expression yields and can retain antigen-binding.
Open AccessLICHEN: Light-chain Immunoglobulin sequence generation Conditioned on the Heavy chain and Experimental Needs
In developing therapeutic antibodies, the heavy chain is often prioritised due to its higher variability and its central role in antigen binding. An appropriate pairing of the light sequence is however important for antibody function. Here we present LICHEN, a heavy chain conditioned light sequence generation tool that enables collaborative light sequence design by leveraging computational capabilities alongside experimental expertise. LICHEN generates light sequences which are valid (antibodylike), diverse in sequence and structure, and conditioned on a specific heavy chain. LICHEN can also condition on germline and CDRs and automatically filter generated sequences for required properties. This allows LICHEN to be used across multiple antibody development use cases. We carry out experimental validation of the method conditioning only on the heavy sequence and on the heavy sequence and binding information. Our in vitro results show that sequences created by LICHEN have effective expression yields and can retain antigen-binding.
- Open Access
ANARCII: A Generalised Language Model for Antigen Receptor Numbering
Antigen receptor numbering allows the rapid delineation of the antigen-binding regions of antibody and T cell receptor (TCR) sequences, from sequence alone. It also allows the comparison of the vast diversity of antigen receptors in a consistent frame of reference. Numbering of antigen receptors is currently achieved by aligning sequences to a reference set. This approach may result in different numbering, depending on the reference set used or may fail to number query sequences derived from new species or rare sequence types. To address this problem, we have built a new numbering method (ANARCII) which requires no alignment step and is based on a Seq2Seq language model. Our results show that ANARCII can deal with the complexity that arises in experimentally collected sequencing data and generalise to sequences which are highly dissimilar to those in training. In test sets designed to contain challenging and ambiguous sequence patterns ANARCII numbering was identical to existing methods for over 99.99% of conserved residues and over 99.94% for complete CDR regions. The lightweight architecture allows numbering of over 90,000 sequences per minute on a single A100 GPU. Furthermore, the ANARCII package can be conditioned to fit rare sequence types and provide new training data for fine-tuning. We demonstrate that fine-tuned versions of ANARCII can correctly number other immunoglobulin domains such as TCRs and VNARs. Our model is freely available as a web tool ( https://github.com/oxpig/ANARCII ), as well as a package for high throughput numbering of next generation sequencing data ( https://opig.stats.ox.ac.uk/webapps/sabdab-sabpred/sabpred/anarcii/ ).
Open AccessANARCII: A Generalised Language Model for Antigen Receptor Numbering
Antigen receptor numbering allows the rapid delineation of the antigen-binding regions of antibody and T cell receptor (TCR) sequences, from sequence alone. It also allows the comparison of the vast diversity of antigen receptors in a consistent frame of reference. Numbering of antigen receptors is currently achieved by aligning sequences to a reference set. This approach may result in different numbering, depending on the reference set used or may fail to number query sequences derived from new species or rare sequence types. To address this problem, we have built a new numbering method (ANARCII) which requires no alignment step and is based on a Seq2Seq language model. Our results show that ANARCII can deal with the complexity that arises in experimentally collected sequencing data and generalise to sequences which are highly dissimilar to those in training. In test sets designed to contain challenging and ambiguous sequence patterns ANARCII numbering was identical to existing methods for over 99.99% of conserved residues and over 99.94% for complete CDR regions. The lightweight architecture allows numbering of over 90,000 sequences per minute on a single A100 GPU. Furthermore, the ANARCII package can be conditioned to fit rare sequence types and provide new training data for fine-tuning. We demonstrate that fine-tuned versions of ANARCII can correctly number other immunoglobulin domains such as TCRs and VNARs. Our model is freely available as a web tool ( https://github.com/oxpig/ANARCII ), as well as a package for high throughput numbering of next generation sequencing data ( https://opig.stats.ox.ac.uk/webapps/sabdab-sabpred/sabpred/anarcii/ ).
- Open Access
- 24 January 2025
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 90, 102983
Challenges and compromises: Predicting unbound antibody structures with deep learning
- 24 January 2025
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 90, 102983
Open AccessChallenges and compromises: Predicting unbound antibody structures with deep learning
- Open Access
- 10 October 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (D1) , D535-D542
PLAbDab-nano: a database of camelid and shark nanobodies from patents and literature
Nanobodies are essential proteins of the adaptive immune systems of camelid and shark species, complementing conventional antibodies. Properties such as their relatively small size, solubility and high thermostability make VHH (variable heavy domain of the heavy chain) and VNAR (variable new antigen receptor) modalities a promising therapeutic format and a valuable resource for a wide range of biological applications. The volume of academic literature and patents related to nanobodies has risen significantly over the past decade. Here, we present PLAbDab-nano, a nanobody complement to the Patent and Literature Antibody Database (PLAbDab). PLAbDab-nano is a self-updating, searchable repository containing ∼5000 annotated VHH and VNAR sequences. We describe the methods used to curate the entries in PLAbDab-nano, and highlight how PLAbDab-nano could be used to design diverse libraries, as well as find sequences similar to known patented or therapeutic entries. PLAbDab-nano is freely available as a searchable web server (https://opig.stats.ox.ac.uk/webapps/plabdab-nano/).
- 10 October 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (D1) , D535-D542
Open AccessPLAbDab-nano: a database of camelid and shark nanobodies from patents and literature
Nanobodies are essential proteins of the adaptive immune systems of camelid and shark species, complementing conventional antibodies. Properties such as their relatively small size, solubility and high thermostability make VHH (variable heavy domain of the heavy chain) and VNAR (variable new antigen receptor) modalities a promising therapeutic format and a valuable resource for a wide range of biological applications. The volume of academic literature and patents related to nanobodies has risen significantly over the past decade. Here, we present PLAbDab-nano, a nanobody complement to the Patent and Literature Antibody Database (PLAbDab). PLAbDab-nano is a self-updating, searchable repository containing ∼5000 annotated VHH and VNAR sequences. We describe the methods used to curate the entries in PLAbDab-nano, and highlight how PLAbDab-nano could be used to design diverse libraries, as well as find sequences similar to known patented or therapeutic entries. PLAbDab-nano is freely available as a searchable web server (https://opig.stats.ox.ac.uk/webapps/plabdab-nano/).
- Open Access
PLAbDab-nano: a database of camelid and shark nanobodies from patents and literature
Nanobodies are essential proteins of the adaptive immune systems of camelid and shark species, complementing conventional antibodies. Properties such as their relatively small size, solubility and high thermostability make VHH and VNAR modalities a promising therapeutic format and a valuable resource for a wide range of biological applications. The volume of academic literature and patents related to nanobodies has risen significantly over the past decade. Here, we present PLAbDab-nano, a nanobody complement to the Patent and Literature Antibody Database (PLAbDab). PLAbDab-nano is a selfupdating, searchable repository containing approximately 5000 annotated VHH and VNAR sequences. We describe the methods used to curate the entries in PLAbDab-nano, and highlight how PLAbDab-nano could be used to design diverse libraries, as well as find sequences similar to known patented or therapeutic entries. PLAbDab-nano is freely available as a searchable web server ( opig . stats . ox . ac . uk/webapps/plabdab-nano/ ). Graphical
Open AccessPLAbDab-nano: a database of camelid and shark nanobodies from patents and literature
Nanobodies are essential proteins of the adaptive immune systems of camelid and shark species, complementing conventional antibodies. Properties such as their relatively small size, solubility and high thermostability make VHH and VNAR modalities a promising therapeutic format and a valuable resource for a wide range of biological applications. The volume of academic literature and patents related to nanobodies has risen significantly over the past decade. Here, we present PLAbDab-nano, a nanobody complement to the Patent and Literature Antibody Database (PLAbDab). PLAbDab-nano is a selfupdating, searchable repository containing approximately 5000 annotated VHH and VNAR sequences. We describe the methods used to curate the entries in PLAbDab-nano, and highlight how PLAbDab-nano could be used to design diverse libraries, as well as find sequences similar to known patented or therapeutic entries. PLAbDab-nano is freely available as a searchable web server ( opig . stats . ox . ac . uk/webapps/plabdab-nano/ ). Graphical
- Open Access
- 15 July 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (3) , 559-572.e9
Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action
- 15 July 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (3) , 559-572.e9
Open AccessTebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action
- Open Access
The Observed T cell receptor Space database enables paired-chain repertoire mining, coherence analysis and language modelling
T cell activation is governed through T cell receptors (TCRs), heterodimers of two sequence-variable chains (often an alpha [ α ] and beta [ β ] chain) that recognise linear antigen fragments presented on the cell surfaces. Early sequencing technologies limited the study of immune repertoire TCRs to unpaired transcripts, leading to extensive analysis of β -chain data alone as its greater sequence diversity suggested it should dominate antigen recognition. Over time, structural data has revealed that both α and β chains contribute to binding most antigens and highthroughput single-cell handling technologies have been increasingly applied to obtain samples of complete TCR variable region sequences from repertoires. Despite this, there is currently no repository dedicated to the curation of publicly available paired TCR sequence data. We have addressed this gap by creating the Observed T cell receptor Space (OTS) database, a source of consistently processed and annotated, full-length, paired-chain TCR sequencing data from 50 studies and at least 75 individuals. Currently, OTS contains 5.35M redundant (1.63M nonredundant) predominantly human TCR sequences and, based on recent data availability trends, will grow rapidly. We perform an initial analysis of OTS, leading to the identification of pairing biases, public TCRs, and distinct chain coherence patterns relative to antibodies. We also harness the data to build a publicly available paired-chain TCR language model, providing paired embedding representations and a method for residue in-filling that is conditional on the partner chain. OTS will be updated and maintained as a central community resource and is freely downloadable and available as a web application at https://opig.stats.ox.ac.uk/webapps/ots .
Open AccessThe Observed T cell receptor Space database enables paired-chain repertoire mining, coherence analysis and language modelling
T cell activation is governed through T cell receptors (TCRs), heterodimers of two sequence-variable chains (often an alpha [ α ] and beta [ β ] chain) that recognise linear antigen fragments presented on the cell surfaces. Early sequencing technologies limited the study of immune repertoire TCRs to unpaired transcripts, leading to extensive analysis of β -chain data alone as its greater sequence diversity suggested it should dominate antigen recognition. Over time, structural data has revealed that both α and β chains contribute to binding most antigens and highthroughput single-cell handling technologies have been increasingly applied to obtain samples of complete TCR variable region sequences from repertoires. Despite this, there is currently no repository dedicated to the curation of publicly available paired TCR sequence data. We have addressed this gap by creating the Observed T cell receptor Space (OTS) database, a source of consistently processed and annotated, full-length, paired-chain TCR sequencing data from 50 studies and at least 75 individuals. Currently, OTS contains 5.35M redundant (1.63M nonredundant) predominantly human TCR sequences and, based on recent data availability trends, will grow rapidly. We perform an initial analysis of OTS, leading to the identification of pairing biases, public TCRs, and distinct chain coherence patterns relative to antibodies. We also harness the data to build a publicly available paired-chain TCR language model, providing paired embedding representations and a method for residue in-filling that is conditional on the partner chain. OTS will be updated and maintained as a central community resource and is freely downloadable and available as a web application at https://opig.stats.ox.ac.uk/webapps/ots .